129 related articles for article (PubMed ID: 37062514)
1. Maintenance of bone resorption markers in the low premenopausal range during the year following denosumab discontinuation is associated to bone density preservation. The ReoLaus study.
Liebich G; Lamy O; Aubry-Rozier B; Gonzalez-Rodriguez E
Bone; 2023 Jul; 172():116764. PubMed ID: 37062514
[TBL] [Abstract][Full Text] [Related]
2. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
Tutaworn T; Nieves JW; Wang Z; Levin JE; Yoo JE; Lane JM
Osteoporos Int; 2023 Mar; 34(3):573-584. PubMed ID: 36602607
[TBL] [Abstract][Full Text] [Related]
3. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
[TBL] [Abstract][Full Text] [Related]
4. A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains.
Everts-Graber J; Reichenbach S; Ziswiler HR; Studer U; Lehmann T
J Bone Miner Res; 2020 Jul; 35(7):1207-1215. PubMed ID: 31991007
[TBL] [Abstract][Full Text] [Related]
5. The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation.
Makras P; Appelman-Dijkstra NM; Papapoulos SE; van Wissen S; Winter EM; Polyzos SA; Yavropoulou MP; Anastasilakis AD
J Clin Endocrinol Metab; 2021 Sep; 106(10):e4155-e4162. PubMed ID: 33978745
[TBL] [Abstract][Full Text] [Related]
6. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.
Makras P; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Anastasilakis AD
Bone; 2020 Sep; 138():115478. PubMed ID: 32534221
[TBL] [Abstract][Full Text] [Related]
7. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
[TBL] [Abstract][Full Text] [Related]
8. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
[TBL] [Abstract][Full Text] [Related]
9. Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series.
Clifton Goldney D; Pelegrin C; Jerkovich F; Longobardi V; Gonzalez Rodriguez E; Zanchetta MB
Osteoporos Int; 2024 Jan; 35(1):165-171. PubMed ID: 37702746
[TBL] [Abstract][Full Text] [Related]
10. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
Anastasilakis AD; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Makras P
J Bone Miner Res; 2019 Dec; 34(12):2220-2228. PubMed ID: 31433518
[TBL] [Abstract][Full Text] [Related]
11. Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis.
Kocjan T; Rajic AS; Janez A; Vidmar G; Orehek N; Marc J; Ostanek B
Endocr Pract; 2021 Sep; 27(9):941-947. PubMed ID: 34111556
[TBL] [Abstract][Full Text] [Related]
12. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.
Anastasilakis AD; Polyzos SA; Yavropoulou MP; Appelman-Dijkstra NM; Ntenti C; Mandanas S; Papatheodorou A; Makras P
Calcif Tissue Int; 2021 May; 108(5):587-594. PubMed ID: 33386953
[TBL] [Abstract][Full Text] [Related]
14. Bone Loss After Denosumab: Only Partial Protection with Zoledronate.
Reid IR; Horne AM; Mihov B; Gamble GD
Calcif Tissue Int; 2017 Oct; 101(4):371-374. PubMed ID: 28500448
[TBL] [Abstract][Full Text] [Related]
15. Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis.
Hong N; Shin S; Lee S; Kim KJ; Rhee Y
Calcif Tissue Int; 2022 Jul; 111(1):47-55. PubMed ID: 35226133
[TBL] [Abstract][Full Text] [Related]
16. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Saridakis ZG; Digkas D; Bisbinas I; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Osteoporos Int; 2015 Oct; 26(10):2521-7. PubMed ID: 25990355
[TBL] [Abstract][Full Text] [Related]
17. Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.
Shane E; Shiau S; Recker RR; Lappe JM; Agarwal S; Kamanda-Kosseh M; Bucovsky M; Stubby J; Cohen A
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1528-e1540. PubMed ID: 34849989
[TBL] [Abstract][Full Text] [Related]
18. Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study.
Sølling AS; Harsløf T; Langdahl B
J Bone Miner Res; 2021 Jul; 36(7):1245-1254. PubMed ID: 33813753
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study.
Everts-Graber J; Reichenbach S; Gahl B; Ziswiler HR; Studer U; Lehmann T
Bone; 2021 Mar; 144():115830. PubMed ID: 33359006
[TBL] [Abstract][Full Text] [Related]
20. Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study.
Cairoli E; Palmieri S; Goggi G; Roggero L; Arosio M; Chiodini I; Eller-Vainicher C
J Endocrinol Invest; 2018 Aug; 41(8):1005-1013. PubMed ID: 29340971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
